Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temanogrel for microvascular obstruction during PCI
NL-OMON51876Phase 2Completed
- Sponsor
- Arena Pharmaceuticals, Inc.
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronary arteriosclerosis comparing Temanogrel with Placebo (2 arms). Primary endpoint: Change in index of microcirculatory resistance from baseline to post-PCI. Started Aug 2021; status: completed.
02
Drugs
temanogrel
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on NL-OMON51876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51876.